Both longevity medicine and the anti-aging supplement industry use the same vocabulary. Here is a structured framework for telling them apart — and why the distinction matters clinically.
Longevity medicine and the anti-aging supplement industry occupy the same vocabulary, the same media coverage, and increasingly the same clinical settings. Distinguishing them requires specific criteria — not general skepticism and not uncritical acceptance.
The anti-aging industry has spent decades making claims that outrun evidence. The longevity medicine field, now anchored by academic research programs, clinical trials, and serious physician organizations, is attempting to build an evidence base that can support clinical decisions. The risk is that the two are conflated — that patients are sold supplement stacks based on the credibility of the TAME trial or the PEARL trial, when the evidence supporting the supplement and the evidence supporting the drug are categorically different.
Longevity medicine applies clinical evidence standards: RCTs with pre-specified endpoints, peer review, transparency about confidence intervals and negative findings, evidence tiers that acknowledge uncertainty, and separation between what evidence shows and what is recommended clinically. The anti-aging industry systematically applies lower standards: observational associations presented as efficacy evidence, surrogate endpoints presented as hard outcomes, individual case reports presented as clinical validation, and lack of transparency about null results. The distinction is not about whether a compound is pharmaceutical or natural — it is about the evidence standards applied to its evaluation.
Specific warning signs: citing in vitro data as clinical evidence; citing mouse lifespan extension as human evidence without acknowledging translation failure rates; presenting epigenetic clock reductions as biological age reversal without noting that clock score reduction has not been validated as a mortality predictor; citing observational associations as equivalent to RCT evidence; using biological plausibility as a substitute for clinical trial data; and not disclosing confidence intervals or study limitations. These are not necessarily signs of fraud — they may reflect genuine enthusiasm or scientific illiteracy. But they are signs that evidence standards are not being applied.
Longevity medicine is a legitimate and important emerging field. It is also being colonized by commercial interests that apply anti-aging industry standards to clinical claims. A physician practicing longevity medicine should apply the same evidence standards to longevity interventions as to any other clinical decision: what is the study design, what is the endpoint, what is the effect size and confidence interval, and has the finding been replicated? Geroevidence applies these standards systematically so practitioners do not have to evaluate every paper from scratch.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.